Pfizer will dominate $20bn Covid-pill market in 2022, analysis shows
As richer nations rush to purchase supplies, while less affluent countries will have to wait until early 2023 for generic-drug companies to produce large quantities, an analysis shows.
Source: moneyweb.co.za